Glycostem celebrated its 15-year anniversary on July 2nd. Glycostem has been making changes in the life of cancer patients and their families for the past 15 years and will continue to do so in the future.
It is Glycostem’s ambition to cure cancer and they look forward to making more progress in this journey. Glycomstem’s first investigational product oNKord® is proceeding well with patient dosing in the phase I/IIa trial with AML patients. In the meantime they are expanding the indication to more cancer type.
Besides of oNKord®, Glycomstem is in late stage development of CAR-NK therapies, and exploring into TCR NK as the third generation product.
Visit the Glycomstem website for more information: https://www.glycostem.com/